Blue Water Vaccines, Inc.

The momentum for this stock is not very good. Blue Water Vaccines, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Blue Water Vaccines, Inc..
Log in to see more information.

News

Blue Water Gets Regulatory Nod From Ohio State To Operate As Pharmaceutical Wholesaler
Blue Water Gets Regulatory Nod From Ohio State To Operate As Pharmaceutical Wholesaler

Benzinga Blue Water Biotech, Inc. (NASDAQ: BWV) received a\n more…

Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate
Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate

Benzinga Blue Water Biotech Inc (NASDAQ: BWV) has released preliminary preclinical data that supports the potential use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for the development of a novel\n more…

Short Volatility Alert: Blue Water Biotech
Short Volatility Alert: Blue Water Biotech

Benzinga On Wednesday, shares of Blue Water Biotech (NASDAQ: BWV) experienced volatile short activity. After the activity, the stock price went up +62.03% to $1.28. The overall sentiment for BWV has been Bullish.\n more…

Short Volatility Alert: Blue Water Biotech
Short Volatility Alert: Blue Water Biotech

Benzinga On Wednesday, shares of Blue Water Biotech (NASDAQ: BWV) experienced volatile short activity. After the activity, the stock price went up +62.03% to $1.28. The overall sentiment for BWV has been Bullish.\n more…

Why Blue Water Biotech (BWV) Stock Is Ripping Higher Wednesday
Why Blue Water Biotech (BWV) Stock Is Ripping Higher Wednesday

Benzinga Blue Water Biotech, Inc. (NASDAQ: BWV) shares are ripping higher on Wednesday after the company announced the acquisition of six FDA-approved drugs across various treatment areas. The Details:\n more…

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Globe Newswire Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas\n\n Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas\n\nCINCINNATI, Ohio, June 14, 2023 (GLOBE NEWSWIRE) -- Blue Water ...\n more…